Table 2.

Clinical characteristics of participants in a crossover trial assessing the dialyzability of four β-blockers

Subject Identification	BB002	BB003	BB004	BB005	BB006	BB007	BB008	BB009
Sex	Man	Man	Man	Woman	Man	Man	Man	Man
Ethnicity	White	White	White	White	Aboriginal	Black Canadian	White	White
Age, yr	42	73	66	28	47	72	80	53
Weight, kg	94	129	54	82	118	90	90	106
Height, m	1.7	1.9	1.7	1.5	1.7	1.6	1.7	1.8
Body mass index, kg/m2	32.2	35.6	19.2	37.7	38.7	33.8	30.3	33.6
Residual kidney output, ml/d	300	425	260	Anuric	Anuric	500	300	300
Cause of CKD	RPGN	DM and HTN	PCKD	Renux nephropath	DM and HTN	HTN	DM and HTN	DM
Dialysis duration, h	4	4	3	3.5	4	4	3	4
Dialysis frequency, sessions per week	3	3	3	3	3	3	3	3
Dialyzer type	FX800	FX1000	FX600	FX600	FX1000	FX800	FX600	Revaclear Max 400
Mean blood flow rate, ml/mina	382	323	354	397	287	385	325	313
Dialysis adequacy, Kt/Va	1.5±0.04	1.1±0.12	1.4±0.11	1.6±0.15	1.2±0.02	1.6±0.03	1.0±0.04	1.1±0.03
Vascular access	Central catheter	Central catheter	Fistula	Fistula	Central catheter	Central catheter	Fistula	Fistula
Hematocrit, predialysisa	0.27±0.01	0.30±0.01	0.33±0.01	0.29±0.01	0.27±0.01	0.28±0.01	0.29±0.02	0.35±0.01
Hematocrit, postdialysisa	0.24±0.01	0.34±0.02	0.36±0.01	0.33±0.01	0.28±0.01	0.30±0.01	0.32±0.03	0.37±0.01

RPGN, rapidly progressive GN; DM, diabetes mellitus; HTN, hypertension; PCKD, polycystic kidney disease.

^aMean over the four dialysis sessions ±SD.